Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Thurm · SciRah

Researcher profile · Semantic Scholar

H. Thurm

Share profile

H. Thurm — researcher profile on SciRah

h-index: 23
Works: 65
Citations: 4,280

Most-cited papers

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
A. Shaw, T. Bauer, F. de Marinis, E. Felip +10 more
2020New England Journal of Medicine859 citations Open access
Semantic Scholar
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
B. Solomon, B. Besse, T. Bauer, E. Felip +18 more
2018The Lancet Oncology682 citations
Semantic Scholar
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
N. Lee, R. Ferris, A. Psyrri, R. Haddad +17 more
2021The Lancet Oncology511 citations
Semantic Scholar
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
A. Shaw, B. Solomon, B. Besse, T. Bauer +15 more
2019Journal of Clinical Oncology346 citations Open access
Semantic Scholar
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
A. Shaw, B. Solomon, R. Chiari, Gregory Riely +12 more
2019The Lancet Oncology304 citations
Semantic Scholar
FIVE‐AMINOLEVULINIC ACID FOR FLUORESCENCE‐GUIDED RESECTION OF RECURRENT MALIGNANT GLIOMAS: A PHASE II STUDY
A. Nabavi, H. Thurm, Basilios Zountsas, T. Pietsch +3 more
2009Neurosurgery190 citations
Semantic Scholar
Clinical Management of Adverse Events Associated with Lorlatinib.
T. Bauer, E. Felip, B. Solomon, H. Thurm +3 more
2019The Oncologist160 citations Open access
Semantic Scholar
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
K. Goldsmith, Julie R. Park, K. Kayser, J. Malvar +31 more
2023Nature Medicine136 citations Open access
Semantic Scholar
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
B. Solomon, T. Bauer, S. Ignatius Ou, Geoffrey Liu +11 more
2022Journal of Clinical Oncology106 citations Open access
Semantic Scholar
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
E. Felip, A. Shaw, A. Bearz, D. Camidge +10 more
2021Annals of Oncology106 citations Open access
Semantic Scholar
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
T. Bauer, A. Shaw, M. Johnson, A. Navarro +6 more
2020Targeted oncology104 citations Open access
Semantic Scholar
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.
D. Spigel, M. Edelman, T. Mok, K. O'Byrne +4 more
2012Clinical Lung Cancer89 citations
Semantic Scholar
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
H. Thurm, Sebastian Ebel, C. Kentenich, Alice Hemsen +7 more
2003Clinical Cancer Research82 citations
Semantic Scholar
910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
E. Cohen, R. Ferris, A. Psyrri, R. Haddad +16 more
2020Annals of Oncology48 citations Open access
Semantic Scholar
BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.
T. Seiwert, P. Clement, D. Cupissol, J. D. del Campo +4 more
201045 citations
Semantic Scholar
Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations.
A. Bearz, J. Martini, J. Jassem, Sang-We Kim +11 more
2023Journal of Thoracic Oncology39 citations Open access
Semantic Scholar
OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer
B. Solomon, A. Shaw, S. Ou, B. Besse +13 more
201736 citations Open access
Semantic Scholar
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
D. Adkins, Jin-Ching Lin, A. Sacco, J. Ley +14 more
2021Oral Oncology35 citations Open access
Semantic Scholar
Oncogenic transformation induced by the Qin protein is correlated with transcriptional repression.
Jian Li, H. Thurm, H.-W. Chang, J. Iacovoni +1 more
1997Proceedings of the National Academy of Sciences of the United States of America35 citations Open access
Semantic Scholar
Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer
Joseph Chen, A. Ruiz-Garcia, L. James, G. Peltz +3 more
2021Clinical pharmacology and therapy29 citations Open access
Semantic Scholar
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
J. Mazières, L. Iadeluca, A. Shaw, B. Solomon +10 more
2022Lung Cancer28 citations Open access
Semantic Scholar
Factors Associated with Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
I. Dagogo-Jack, A. Abbattista, J. Murphy, S. Krulewicz +8 more
2022Journal of Thoracic Oncology23 citations Open access
Semantic Scholar
Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.
K. Goldsmith, K. Kayser, S. Groshen, M. Chioda +11 more
202023 citations
Semantic Scholar
LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study
B. Solomon, T. Bauer, F. de Marinis, E. Felip +10 more
202023 citations Open access
Semantic Scholar
OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6
S. Ou, A. Shaw, Gregory Riely, R. Chiari +6 more
2018Journal of Thoracic Oncology23 citations Open access
Semantic Scholar
Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.
B. Besse, B. Solomon, E. Felip, T. Bauer +15 more
201819 citations
Semantic Scholar
The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC).
D. Spigel, M. Edelman, T. Mok, K. O'Byrne +4 more
201218 citations
Semantic Scholar
Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors
R. Sullivan, R. Amaria, D. Lawrence, J. Brennan +8 more
201517 citations
Semantic Scholar
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
S. Peters, A. Shaw, B. Besse, E. Felip +14 more
2020Lung Cancer16 citations
Semantic Scholar
Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
T. Seto, H. Hayashi, M. Satouchi, Y. Goto +13 more
2020Cancer Science15 citations Open access
Semantic Scholar
Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).
D. Adkins, Jin-Ching Lin, A. Sacco, J. Ley +9 more
2019Journal of Clinical Oncology14 citations
Semantic Scholar
Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations.
B. Solomon, J. Martini, S. Ou, R. Chiari +8 more
2018Annals of Oncology14 citations Open access
Semantic Scholar
Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) andALKkinase domain mutations
A. Shaw, J. Martini, B. Besse, T. Bauer +14 more
2018Clinical Trials14 citations
Semantic Scholar
Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).
A. Shaw, J. Martini, B. Besse, T. Bauer +14 more
2019Journal of Clinical Oncology13 citations
Semantic Scholar
Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study
Geoffrey Liu, B. Solomon, J. Mazières, Dong-Wan Kim +6 more
2025The Oncologist9 citations Open access
Semantic Scholar
Journal Pre-proof Factors Associated with Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies
I. Dagogo-Jack, A. Abbattista, J. F. Murphy, S. Krulewicz +10 more
20229 citations
Semantic Scholar
MA08.05 Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study
T. Bauer, A. Shaw, M. Johnson, A. Navarro +5 more
2018Journal of Thoracic Oncology9 citations Open access
Semantic Scholar
Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid tumors.
J. Vermorken, J. Machiels, S. Rottey, H. Thurm +2 more
20108 citations
Semantic Scholar
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
Joseph Chen, A. Bearz, Dong-Wan Kim, H. Mamdani +13 more
2023Clinical Pharmacokinetics7 citations Open access
Semantic Scholar
979P Long-term intracranial safety and efficacy analyses from the phase III CROWN study
A. Bearz, E. Felip, J. Mazières, F. de Marinis +7 more
2022Annals of Oncology7 citations Open access
Semantic Scholar
Abstract P2-16-01: A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC)
V. Diéras, D. Yardley, G. Romieu, V. Valero +6 more
20137 citations
Semantic Scholar
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
A. Bearz, J. Martini, J. Jassem, Sang-We Kim +11 more
2022Journal of Clinical Oncology5 citations
Semantic Scholar
MA06.08 Kinetics and Management of Adverse Events Associated with Lorlatinib after 5 Years of Follow-Up in the CROWN Study
T. Bauer, B. Solomon, J. Mazières, D.-W. Kim +6 more
2024Journal of Thoracic Oncology3 citations
Semantic Scholar
MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC
J. Mazières, L. Iadeluca, A. Shaw, B. Solomon +10 more
20213 citations Open access
Semantic Scholar
Abstract CT025: Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC)
T. Bauer, J. Martini, B. Besse, Chia-Chi Lin +13 more
2020Tumor Biology3 citations
Semantic Scholar
Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting
D. Camidge, B. Solomon, E. Felip, B. Besse +8 more
2019Annals of Oncology3 citations Open access
Semantic Scholar
Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).
S. Peters, A. Shaw, B. Besse, E. Felip +13 more
2018Annals of Oncology3 citations Open access
Semantic Scholar
Response to “Lorlatinib Exposed: A Far from Optimal Dose”
Joseph Chen, A. Ruiz-Garcia, L. James, G. Peltz +3 more
2022Clinical pharmacology and therapy2 citations
Semantic Scholar
Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations
A. Bearz, J. Martini, J. Jassem, Sang-We Kim +11 more
2021Clinical research2 citations
Semantic Scholar
1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)
B. Solomon, T. Mok, H. Hayashi, A. Bearz +8 more
2021Annals of Oncology2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Solomon×25
Invite
B. Solomon — researcher profile on SciRah
A. Shaw×24
Invite
A. Shaw — researcher profile on SciRah
T. Bauer×19
Invite
T. Bauer — researcher profile on SciRah
G. Peltz×19
Invite
G. Peltz — researcher profile on SciRah

×16

Invite

A. Abbattista — researcher profile on SciRah

Invite

J. Martini — researcher profile on SciRah

Invite

E. Felip — researcher profile on SciRah

Invite

B. Besse — researcher profile on SciRah

Invite

A. Bearz — researcher profile on SciRah

Invite

J. Clancy — researcher profile on SciRah

Invite

A. Polli — researcher profile on SciRah

Invite

R. Soo — researcher profile on SciRah